HomeTrialNCT07160257
🔬NCT07160257Phase 1RECRUITING

A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus

Study Summary

The primary objective of this study is to determine the effect of maridebart cafraglutide relative to placebo on insulin sensitivity in participants with Type 2 Diabetes Mellitus (T2DM) treated with stable dose of metformin.

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment70 participants
Primary Completion
Lead SponsorAmgen
Data Retrieved2026-04-13 18:29:34.158231+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.